Bengisu Kevser Bulduk
Research Subjects
Bengisu Kevser Bulduk has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Lourdes Martorell
Hospital Universitari Institut Pere Mata (HUIPM), Institut d'Investigació Sanitària Pere Virgili (IISPV-CERCA), Universitat Rovira i Virgili (URV), CIBERSAM-ISCIII
5 shared publications - Juan Tortajada Valero
Hospital Universitari Institut Pere Mata (HUIPM) Reus Catalonia Spain
4 shared publications - Alba Valiente-Pallejà
Hospital Universitari Institut Pere Mata (HUIPM) Reus Catalonia Spain
3 shared publications - Elisabet Vilella
Hospital Universitari Institut Pere Mata (HUIPM), Institute de Recerca Biomédica Catalunya Sud (IRB-CatSud) previously IISPV-CERCA, Universitat Rovira i Virgili (URV), Reus, Spain
3 shared publications - Gerard Muntané
Institut de Recerca Biomèdica Catalunya Sud, Reus, Spain
3 shared publications Elisabet Vilella
Hospital Universitari Institut Pere Mata (HUIPM), Reus, Catalonia, Spain; Institut d'Investigació Sanitària Pere Virgili (IISPV-CERCA), Universitat Rovira i Virgili (URV), Reus, Catalonia, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III, Madrid, Spain
2 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by Wiley in General Psychiatry
- Vol. 39 (3) , e70023
Clinical outcomes of mitochondrial‐enhancing nutraceutical supplementation in psychiatric disorders: A systematic review
Background: Nutraceutical supplementation targeting mitochondrial function has been proposed as a beneficial therapeutic strategy to improve physical and mental health in psychiatric patients. Aims: To summarise the results of studies evaluating nutraceutical supplementation targeting mitochondrial function in patients with psychiatric disorders. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines, we searched PubMed, Embase and Scopus databases from 1 January 2007 to 30 April 2024. Reports were included if they evaluated outcomes of nutraceutical supplementation in patients with psychiatric disorders or related conditions. Additionally, we performed a risk‐of‐bias analysis of the studies compatible with the RoB2 tool. Results: Of the 2061 records identified, 122 studies met the inclusion criteria, evaluating vitamin D3, N‐acetylcysteine, acetyl‐L‐carnitine, coenzyme Q10, alpha‐lipoic acid, magnesium, vitamin B6, vitamin B7, folic acid, vitamin B12, vitamin E, vitamin A, vitamin C and vitamin B3. The most studied nutraceuticals were vitamin D3 (27.05%) and N‐acetylcysteine (15.6%). Among randomised controlled clinical trials (RCTs), vitamin D3 was the most extensively investigated and accounted for the highest number of trials reporting improvements in clinical outcomes, although findings were heterogeneous. Notably, 14.8% of the studies evaluated combinations of three or more nutraceuticals. Dietary supplements were extensively evaluated for autism spectrum disorder (28 studies), schizophrenia spectrum disorder (27 studies), major depressive disorder or related depressive symptoms (22 studies), attention‐deficit hyperactivity disorder (9 studies) and bipolar spectrum disorder (6 studies). A substantial proportion of studies were not RCTs but open‐label single‐arm trials or case reports. Significant heterogeneity was observed in the nutraceutical components used, treatment duration and the outcomes assessed. Overall, the risk of bias was high, and the methodological quality was generally low. Conclusions: Promising findings in nutraceutical studies for psychiatric disorders face challenges, including small sample sizes, short follow‐up periods and a lack of treatment standardisation. Future research requires robust RCTs with standardised protocols and validated biomarkers of efficacy.
- 1 June 2026
- Published by Wiley in General Psychiatry
- Vol. 39 (3) , e70023
Open AccessClinical outcomes of mitochondrial‐enhancing nutraceutical supplementation in psychiatric disorders: A systematic review
Background: Nutraceutical supplementation targeting mitochondrial function has been proposed as a beneficial therapeutic strategy to improve physical and mental health in psychiatric patients. Aims: To summarise the results of studies evaluating nutraceutical supplementation targeting mitochondrial function in patients with psychiatric disorders. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines, we searched PubMed, Embase and Scopus databases from 1 January 2007 to 30 April 2024. Reports were included if they evaluated outcomes of nutraceutical supplementation in patients with psychiatric disorders or related conditions. Additionally, we performed a risk‐of‐bias analysis of the studies compatible with the RoB2 tool. Results: Of the 2061 records identified, 122 studies met the inclusion criteria, evaluating vitamin D3, N‐acetylcysteine, acetyl‐L‐carnitine, coenzyme Q10, alpha‐lipoic acid, magnesium, vitamin B6, vitamin B7, folic acid, vitamin B12, vitamin E, vitamin A, vitamin C and vitamin B3. The most studied nutraceuticals were vitamin D3 (27.05%) and N‐acetylcysteine (15.6%). Among randomised controlled clinical trials (RCTs), vitamin D3 was the most extensively investigated and accounted for the highest number of trials reporting improvements in clinical outcomes, although findings were heterogeneous. Notably, 14.8% of the studies evaluated combinations of three or more nutraceuticals. Dietary supplements were extensively evaluated for autism spectrum disorder (28 studies), schizophrenia spectrum disorder (27 studies), major depressive disorder or related depressive symptoms (22 studies), attention‐deficit hyperactivity disorder (9 studies) and bipolar spectrum disorder (6 studies). A substantial proportion of studies were not RCTs but open‐label single‐arm trials or case reports. Significant heterogeneity was observed in the nutraceutical components used, treatment duration and the outcomes assessed. Overall, the risk of bias was high, and the methodological quality was generally low. Conclusions: Promising findings in nutraceutical studies for psychiatric disorders face challenges, including small sample sizes, short follow‐up periods and a lack of treatment standardisation. Future research requires robust RCTs with standardised protocols and validated biomarkers of efficacy.
- Open Access
- 1 May 2024
- Published by Elsevier in Psychiatry Research
- Vol. 337, 115928
High number of mitochondrial DNA alterations in postmortem brain tissue of patients with schizophrenia compared to healthy controls
- 1 May 2024
- Published by Elsevier in Psychiatry Research
- Vol. 337, 115928
Open AccessHigh number of mitochondrial DNA alterations in postmortem brain tissue of patients with schizophrenia compared to healthy controls
- 7 July 2023
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 164, 440-446
High blood levels of brain-derived neurotrophic factor (BDNF) mRNA in early psychosis are associated with inflammatory markers
- 7 July 2023
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 164, 440-446
High blood levels of brain-derived neurotrophic factor (BDNF) mRNA in early psychosis are associated with inflammatory markers
- 1 October 2021
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 51, e236-e237
TH79. MITOCHONDRIAL DNA ALTERATIONS IN THE POSTMORTEM BRAIN OF PSYCHIATRIC DISEASES: A SYSTEMATIC REVIEW
- 1 October 2021
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 51, e236-e237
TH79. MITOCHONDRIAL DNA ALTERATIONS IN THE POSTMORTEM BRAIN OF PSYCHIATRIC DISEASES: A SYSTEMATIC REVIEW
- 1 March 2020
- Published by SAGE Publications in Genetic Testing and Molecular Biomarkers
- Vol. 24 (3) , 165-170
A Novel Amplification-Refractory Mutation System-PCR Strategy to Screen MT-TL1 Pathogenic Variants in Patient Repositories
Aim: Pathogenic variants within mitochondrial tRNA and rRNA genes negatively affect protein synthesis function and cause oxidative phosphorylation defects. The majority of mitochondrial cytopathies are caused by pathogenic point variants within the mitochondrial tRNA gene for leucine (MT-TL1). This study was designed to evaluate a novel amplification-refractory mutation system (ARMS)-PCR based assay to screen patient samples with a clinical diagnosis of mitochondrial cytopathies. Methods: Tissue DNA samples from 219 affected individuals were screened for the pathogenic variants m.3271T>C, m.3291Ty >C, m.3303C>T, m.3256C>T, and m.3260A>G along with the most frequent m.3243A>G mutation in the MT-TL1 gene. The assay included a “High Resolution Melt curve analysis” to enhance detection limits. The precision of the assay was verified using synthetic controls with variant heteroplasmy ratios. Results: The screening identified the second reported m.3303C>T case as well as two patients with m.3243A>G variants and a rare variant exhibiting m.3290T>C. Conclusion: ARMS-PCR is superior to Sanger sequencing for the detection of variations exhibiting low heteroplasmy. These results provide “proof of concepts” for the implementation of this application for future screening of rare mtDNA variations in sample repositories.
- 1 March 2020
- Published by SAGE Publications in Genetic Testing and Molecular Biomarkers
- Vol. 24 (3) , 165-170
A Novel Amplification-Refractory Mutation System-PCR Strategy to Screen MT-TL1 Pathogenic Variants in Patient Repositories
Aim: Pathogenic variants within mitochondrial tRNA and rRNA genes negatively affect protein synthesis function and cause oxidative phosphorylation defects. The majority of mitochondrial cytopathies are caused by pathogenic point variants within the mitochondrial tRNA gene for leucine (MT-TL1). This study was designed to evaluate a novel amplification-refractory mutation system (ARMS)-PCR based assay to screen patient samples with a clinical diagnosis of mitochondrial cytopathies. Methods: Tissue DNA samples from 219 affected individuals were screened for the pathogenic variants m.3271T>C, m.3291Ty >C, m.3303C>T, m.3256C>T, and m.3260A>G along with the most frequent m.3243A>G mutation in the MT-TL1 gene. The assay included a “High Resolution Melt curve analysis” to enhance detection limits. The precision of the assay was verified using synthetic controls with variant heteroplasmy ratios. Results: The screening identified the second reported m.3303C>T case as well as two patients with m.3243A>G variants and a rare variant exhibiting m.3290T>C. Conclusion: ARMS-PCR is superior to Sanger sequencing for the detection of variations exhibiting low heteroplasmy. These results provide “proof of concepts” for the implementation of this application for future screening of rare mtDNA variations in sample repositories.
- 18 December 2018
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 44 (6) , 769-777
A single-tube multiplex qPCR assay for mitochondrial DNA (mtDNA) copy number assessment
Objective: Detection of mtDNA copy number is required for diagnosis of mtDNA depletion. Multiplex quantification of mtDNA in blood samples was claimed via normalizing to a nuclear single copy gene using qPCR. This is not possible in high mtDNA samples due to template abundance. Multiplex qPCR assays cannot be normalized to single copy sequences of the nuclear genome. Methods: mtDNA quantification was tested normalizing to a single copy nuclear gene via singleplex and multiplex reactions. Failure in normalization directed to design and test targeting multi-copy 18S rDNA gene with success. mtDNA quantification was standardized both in separate and multiplexed single-tube reactions based on molecular beacon technology. Results: mtDNA copy number assessment cannot be normalized to a single copy sequence in high-copy-number tissues. However, normalizing mtDNA to the nuclear 18S rDNA multiple copy sequence is amenable to be standardized in single tube. When compared, multiplexing exhibited higher resolution power for quantification of mtDNA in various samples from the most abundant to the scant ones. Conclusion: We describe a multiplex assay that can be translated as a standard technique for single-tube quantification of mtDNA copy number. Our findings show higher accuracy and reproducibility over canonical approach, reducing cost and error rate.
- 18 December 2018
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 44 (6) , 769-777
A single-tube multiplex qPCR assay for mitochondrial DNA (mtDNA) copy number assessment
Objective: Detection of mtDNA copy number is required for diagnosis of mtDNA depletion. Multiplex quantification of mtDNA in blood samples was claimed via normalizing to a nuclear single copy gene using qPCR. This is not possible in high mtDNA samples due to template abundance. Multiplex qPCR assays cannot be normalized to single copy sequences of the nuclear genome. Methods: mtDNA quantification was tested normalizing to a single copy nuclear gene via singleplex and multiplex reactions. Failure in normalization directed to design and test targeting multi-copy 18S rDNA gene with success. mtDNA quantification was standardized both in separate and multiplexed single-tube reactions based on molecular beacon technology. Results: mtDNA copy number assessment cannot be normalized to a single copy sequence in high-copy-number tissues. However, normalizing mtDNA to the nuclear 18S rDNA multiple copy sequence is amenable to be standardized in single tube. When compared, multiplexing exhibited higher resolution power for quantification of mtDNA in various samples from the most abundant to the scant ones. Conclusion: We describe a multiplex assay that can be translated as a standard technique for single-tube quantification of mtDNA copy number. Our findings show higher accuracy and reproducibility over canonical approach, reducing cost and error rate.